DoD tests AI models that make it easy to switch from vendors like Palantir
Investing.com - Evercore ISI has raised its price target on ICON plc (NASDAQ:ICLR) to $240.00 from $170.00 while maintaining an Outperform rating on the clinical research organization. The new target approaches the high end of analyst estimates, which currently range from $144 to $243, according to InvestingPro data. The stock has shown strong momentum, gaining over 14% in the past week.
The firm cited improving demand environment and above-expectations book-to-bill ratio in the second quarter as key factors behind the significant price target increase. Evercore noted that while elevated cancellations remain a concern, revenue improvement signals a positive inflection in the business cycle. InvestingPro analysis shows ICON maintains a strong financial health score of 3.34 (rated as "GREAT"), suggesting robust operational fundamentals despite near-term challenges.
ICON is benefiting from stable pharmaceutical demand, improved biotech sector performance, and higher cardio-metabolic business, according to Evercore’s analysis. The research firm also highlighted ICON’s market share gains as contributing to its performance. With a market capitalization of $15.66 billion and a healthy free cash flow yield of 7%, ICON demonstrates strong financial fundamentals. For deeper insights into ICON’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
Evercore has revised its earnings per share estimates upward, raising its 2025 EPS projection from $12.74 to $13.10 and its 2026 forecast from $13.98 to $14.12. The new price target represents approximately 13 times 2026 EBITDA or 20 times price-to-earnings ratio.
The updated valuation remains around the midpoint of ICON’s 10-year average, which Evercore considers attractive given the potential for additional positive EPS revisions over the next 12-24 months. Evercore continues to view ICON as a "structural winner" in the clinical CRO space.
In other recent news, ICON plc reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings of $3.26 per diluted share, surpassing the estimated $3.19. The company’s revenue for the quarter was $2.02 billion, which was higher than the consensus estimate of $1.98 billion, despite being a 4.8% decrease from the same quarter last year. ICON also raised its full-year guidance, signaling a positive outlook for the remainder of the year. Leerink Partners responded to ICON’s performance by raising its price target for the company from $195 to $240, maintaining an Outperform rating due to significant outperformance in gross bookings. Similarly, Baird upgraded ICON’s stock rating from Neutral to Outperform, raising its price target to $224 from $150. Baird noted that while the financial numbers were not ideal, the company shows signs of recovery. These developments highlight a period of significant activity and analyst interest in ICON plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.